KURA
Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
Kura Oncology, Inc. (KURA) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (C).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | B (3.3) | C+ (2.7) | C (2.4) | C+ (2.6) | C+ (2.8) |
| 2026-11-06 | B- (3.0) | B+ (3.6) | B- (2.9) | C+ (2.8) | C+ (2.7) | B- (3.0) |
| 2026-10-30 | B- (3.0) | B+ (3.5) | B- (3.0) | B (3.4) | C+ (2.7) | B- (3.1) |
| 2026-10-23 | B- (3.0) | B+ (3.5) | B- (2.9) | B- (3.0) | C+ (2.6) | B- (3.0) |
| 2026-10-16 | B- (3.0) | B+ (3.5) | B- (2.9) | B- (2.9) | C+ (2.6) | B- (3.0) |